Bionano laboratories announces a second category i cpt code for ogm established by the ama; this one for use in whole genome analysis for constitutional genetic disorders

San diego, may 19, 2025 (globe newswire) -- bionano laboratories, a wholly-owned subsidiary of bionano genomics, inc. (nasdaq: bngo) that offers clia-certified laboratory developed tests (ldts) based on optical genome mapping (ogm), today announced that the editorial panel of the american medical association (ama) established a new category i current procedural terminology (cpt®) code for the use of ogm in cytogenomic genome-wide analysis to detect structural and copy number variations related to constitutional genetic disorders. the cpt code is a key component in obtaining reimbursement for the ogm-dx™ postnatal whole genome sv and ogm-dx™ prenatal whole genome sv ldts from third party payers.
BNGO Ratings Summary
BNGO Quant Ranking